News

‘It will be a little bit different this year.’ Here’s what you need to know about fall vaccines.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Moderna: RSV Upside Slim, Cash Burn Heavy

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
Verywell Health on MSN10d

Who Should Get the RSV Vaccine This Year?

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also ...
BioPharma Dive13d

Moderna to lay off 10% of workforce in ‘difficult but necessary step’

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

FDA considering pulling authorization of Pfizer’s COVID-19 vaccine for healthy children under 5

The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...
Fierce Pharma13d

Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna plans to slash 10% of workforce as COVID shot sales slow

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
Insider Monkey1mon

Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults

Moderna Inc. (NASDAQ: MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...